ORIGINAL COMMUNICATION



Decreased inflammatory cytokine production of antigen-specific CD4⁺ T cells in NMDA receptor encephalitis

Le-Minh Dao^{1,2} · Marie-Luise Machule^{1,2} · Petra Bacher^{3,4} · Julius Hoffmann¹ · Lam-Thanh Ly^{1,2} · Florian Wegner⁵ · Alexander Scheffold³ · Harald Prüss^{1,2}

Received: 22 August 2020 / Revised: 11 December 2020 / Accepted: 14 December 2020 / Published online: 13 January 2021 © The Author(s) 2021

Abstract

Anti-N-methyl-D-aspartate-receptor (NMDAR) encephalitis is the most common autoimmune encephalitis with psychosis, amnesia, seizures and dyskinesias. The disease is mediated by pathogenic autoantibodies against the NR1 subunit that disrupt NMDAR function. Antibody infusion into mouse brains can recapitulate encephalitis symptoms, while active immunization resulted also in strong T cell infiltration into the hippocampus. However, whether T cells react against NMDAR and their specific contribution to disease development are poorly understood. Here we characterized the ex vivo frequency and phenotype of circulating CD4⁺ T helper (T_H) cells reactive to NR1 protein using antigen-reactive T cell enrichment (ARTE) in 24 patients with NMDAR encephalitis, 13 patients with LGI1 encephalitis and 51 matched controls. Unexpectedly, patients with NMDAR encephalitis had lower frequencies of CD154-expressing NR1-reactive T_H cells than healthy controls and produced significantly less inflammatory cytokines. No difference was seen in T cells reactive to the synaptic target LGI1 (Leucine-rich glioma-inactivated 1), ubiquitous *Candida* antigens or neoantigens, suggesting that the findings are disease-specific and not related to therapeutic immunosuppression. Also, patients with LGI1 encephalitis showed unaltered numbers of LGI1 antigen-reactive T cells. The data reveal disease-specific functional alterations of circulating NMDAR-reactive T_H cells in patients with NMDAR encephalitis and challenge the idea that increased pro-inflammatory NMDAR-reactive T cells contribute to disease pathogenesis.

Keywords NMDAR encephalitis · Autoantibodies · T cells · Cytokines · Antigen-reactive T cell enrichment · LGI1

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00415-020-10371-y) contains supplementary material, which is available to authorized users.

Le-Minh Dao and Marie-Luise Machule have contributed equally to the work.

Harald Prüss harald.pruess@charite.de

- ¹ German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany
- ² Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany
- ³ Institute of Immunology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
- ⁴ Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
- ⁵ Department of Neurology, Hannover Medical School, Hannover, Germany

Introduction

Autoantibodies targeting the NR1 subunit of the N-methyl-D-aspartate-receptor (NMDAR) are the hallmark of NMDAR encephalitis (NMDAR-E) [7]. The antibodies are directly functional, mainly by internalization of NMDAR and subsequent disruption of glutamatergic transmission [14, 18]. Presence of the antibodies in the cerebrospinal fluid (CSF) results in clinical symptoms ranging from psychosis to amnesia to autonomic dysfunction [6]. The increasing knowledge on these antibodies showed differences to other autoimmune diseases. For example, NR1 antibodies in patients' CSF had only few somatic hypermutations or were even unmutated, suggesting that T cell help might not be required for antibody development [23]. Such germline antibodies were nonetheless pathogenic in established in vitro assays. On the other hand, T helper (T_H) cells typically potentiate antibody secreting cell (ASC)-mediated antibody responses, and active immunization of mice with conformationally stabilized NMDAR protein resulted in profound infiltration of the hippocampus with not only ASC, but also CD4⁺ T cells [11]. CSF cytokine/chemokine signatures, such as increased interleukin-17, interleukin-6 or CXCL10 levels, also suggest a contribution of T cells in NMDAR-E [4, 15], and brain biopsies or autopsies demonstrated infiltrates of CD4⁺ cells as well [3, 16]. However, their antigen specificities are unknown. Until now, the characteristics of NR1-specific T_H cells in patients with NMDAR-E are poorly described. Using antigen-reactive T cell enrichment (ARTE) [2], we therefore quantified and characterized the rare CD4⁺ T_H cells reactive to NR1 protein, focusing on the aminoterminal domain of NR1 which represents the antibodies' major binding epitope [9, 14]. Results provide insight into the immunological cascades leading to NMDAR antibody development and disease pathogenesis, might later help to explain the highly variable clinical spectrum in patients despite similar antibody titers, and could potentially lead to additional therapeutic approaches beyond antibody-directed therapies.

Methods

Cohorts

All clinical investigations were conducted according to Declaration of Helsinki principles. Written informed consent was received from participants at the Centre for Autoimmune Encephalitis, Department of Neurology, Charité – Universitätsmedizin Berlin, prior to inclusion into the

study and analyses were approved by the Charité Institutional Review Board. Participants included (1) 24 patients with NMDAR-E, (2) 33 age- and sex-matched controls for NMDAR-E, (3) 13 patients with LGI1 (Leucine-rich gliomainactivated 1) encephalitis and (4) 18 age- and sex-matched controls for LGI1-E (Table 1). All encephalitis patients fulfilled diagnostic criteria according to current guidelines [10]: (i) high-titer NMDAR autoantibodies in the CSF and high-titer LGI1 autoantibodies in serum, respectively; (ii) the characteristic clinical picture, i.e., multi-stage development of psychiatric abnormalities, amnesia and vegetative dysfunction in NMDAR-E versus limbic encephalitis with working memory deficits, epileptic seizures and mesiotemporal lobe abnormalities in T2/FLAIR MR imaging in LGI1-E. Related to the evolution of the project, different numbers of proteins were tested in the pilot cohort and in the confirmatory cohort and both cohorts overlap only partially as the majority of patients was newly recruited for each cohort. Thus, not all patients underwent T cell activation testing with all antigens, explaining the variable n numbers in the figures.

Proteins for T cell stimulation

We used commercially available NR1 and LG11 proteins (MyBiosource, 964741 and 1378533) with a purity of > 90% for NR1 and > 85% for LG11 according to the manufacturer. We further generated fragments of the extracellular part of the NMDAR NR1 subunit containing the aminoterminal domain (ATD) or the S1 and S2 domains fused together (S1S2) (Fig. 1a). Proteins were expressed as GST-fusion

Table 1 Clinical, epidemiological and treatment data of the cohorts analyzed in this study

	NMDAR-E patients	Young female controls	LGI1-E patients	Aged male controls
Participants (n)	24	33	13	18
Gender	3 M, 21 F	10 M, 23 F	8 M, 5 F	13 M, 5 F
Age (years) (mean±SD)	31.9 ± 11.9	34.4 ± 13.5	68.7±13.1	69.2 ± 10.5
Time after disease onset (months)	27.8 ± 19.0	N/A	30.1 ± 20.3	N/A
Immunotherapy				
Steroids	23 (95.8%)		13 (100%)	
PE/IA	19 (79.2%)		9 (69.2%)	
Rituximab	20 (83.3%)		11 (84.6%)	
IVIGs	13 (54.2%)		7 (53.8%)	
Cyclophosphamide, MTX, bort- ezomib, azathioprine, MMF	5 (20.8%)		1 (7.7%)	
Autoimmune diseases	Thyroid (2), MS (1)	0 (0%)	Glomerulonephritis (1), rheumatoid arthritis (1)	0 (0%)
Tumours	Ovarian carcinoma (1), ovarian teratoma (5)	0 (0%)	Pancreas neuroendo- crine cancer (1)	Throat cancer (1)



Fig. 1 Antigens, flow cytometry gating strategy and CD4⁺ T cell frequencies. ATD (aminoterminal domain), S1 and S2 are extracellular domains of the NR1 subunit of the NMDA receptor, while LGI1 is part of a trans-synaptic protein complex that regulates voltage-gated potassium channels (**a**). All four proteins (commercial NR1 and LGI1 plus *E.coli*-expressed ATD and S1S2) used for antigen stimulation in this study showed high purity in coomassie staining after gel electrophoresis (**b**; ATD+GST tag=68 kDa, S1S2+GST tag=57 kDa, LGI1=64 kDa, NR1=68 kDa). Based on CD4 expression using

proteins in *E. coli* and purified via glutathione-SepharoseTM 4B (GE Healthcare, 52-2303-00). They showed > 80% purity in coomassie staining after gel electrophoresis based on comparison to the commercial proteins (Fig. 1b).

Antigen-reactive T cell enrichment (ARTE)

Enrichment of NMDAR/LGI1 antigen-specific T cells followed established protocols [2]. In brief, peripheral blood mononuclear cells (PBMC) were isolated from BD Vacutainer[®] CPTTM venous blood samples, washed with PBS, quantified and resuspended in RPMI with 5% human AB serum (Sigma-Aldrich, H4522). 1×10^7 cells in 1 ml were incubated in 12-well plates for 12 h at 37 °C with 5% CO₂. Each well was stimulated with 10 µg autoantigen, together with negative and positive controls for 7 h at 37 °C. One sample per participant remained unstimulated to determine the ratio of CD4+T cells (original fraction, ORI) from PBMCs to allow calculation of the CD154⁺ cell frequency for each sample.

Internalization of CD154 on activated T cells was inhibited during stimulation by blocking CD40 on antigenpresenting cells with 1 µg/ml CD40 antibodies (Miltenyi, 130-094-133, 100 µg/ml). After 5 h, 1 µg/mL Brefeldin A (Sigma-Aldrich, B6542) was added to inhibit the secretion of activation markers. *C. albicans* lysate (Stallergenes Greer,

flow cytometry (c), no differences in CD4⁺ T cell frequencies within PBMCs were observed in all cohorts (d). CD4⁺ T cells were gated for CCR7⁺ CD45RA⁻ to measure dividing memory and naïve CD4⁺ T cells (e). NMDAR-E and LGI1-E patients showed similar distributions of naïve and memory CD4⁺ T cells compared to their respective controls. As expected, older subjects (LGI1-E patients and their controls) had more memory and less naïve T cells than younger subjects (NMDAR-E patients and their controls) (f)

XPM15D3A5) at 20 µg/ml served as positive control. Negative controls were added at equal volumes depending on the autoantigen (PBS for ATD and S1S2; 10 mM Tris–HCL [with 1 mM EDTA and 20% glycerol] for commercial LGI1 and NR1 proteins). Keyhole limpet haemocyanin (KLH) at 200 µg/ml served as neoantigen control (Stellar Biotechnologies, KLH-05NR), confirming that the assay detects all antigen-activated cells including from the naïve repertoire. NMDAR/LGI1-reactive T cells were isolated using the anti-CD154 Microbead Kit human (Miltenyi Biotec, 130-092-658) using MS columns (Miltenyi, 130-042-201).

Flow cytometry

Cells were stained against CD4 (Miltenyi, 130-113-219, Vioblue, human, 1:50; 130-096-652, APC-Vio770, human, 1:11), CD14 (Miltenyi, 130-098-063, FITC, human, 1:11), CD20 (Miltenyi, 130-091-108, FITC, human, 1:11), CD45RA (Miltenyi, 130-096-921, CD45RA-Vio[®]Green, human, 1:11), CD45RO (Miltenyi, 130-099-044, VioBlue, human, 1:11) and CCR7 (Miltenyi, 130-108-286, APC, human, 1:11). Intracellular stainings included IFN-gamma (Miltenyi, 130-109-231, PE, human, 1:11; Biolegend, 502526, PerCP-Cy5.51, human, 1:100), TNF-alpha (Miltenyi, 130-096-755, PE-Vio[®]770, human 1:11) and CD154 (Miltenyi, 130-109-474, PerCP-Vio700, human,

1:11; Miltenyi, 130-092-289, PE, human, 1:11). Samples were measured with flow cytometry (BD FACSCanto II, BD, 338962) and analyzed with FlowJo[®] (BD, FlowJoTM v10.5.3) (Fig. 1c, e).

Statistical analysis

GraphPad Prism software (GraphPad Software, Version 7.5) was used for statistical analysis. For all measurements, background activity (CD154⁺ T cells in PBS/buffer control samples) was subtracted. The Shapiro–Wilk and D'Agostino Pearson tests were used to test for normal distribution of CD154⁺ T cell frequencies. As normal distribution was found, all 4 cohorts were analyzed with one-way ANOVA and corrected for multiple comparisons with Tukey tests. If two groups were compared, two-sided t-tests were used for independent samples. In all graphs, average values are shown with standard deviations. The significance level was defined as p < 0.05.

Results

Study participants

Study cohorts included patients with NMDAR-E (n = 24), patients with LGI1-E encephalitis (LGI1-E) (n = 13) and respective healthy controls. As NMDAR-E is a disease of predominantly young female patients and LGI1-E a disease of aged male patients, two different age- and sex-matched groups of unaffected controls were recruited (n = 33 and n = 18, respectively). The mean age was 31.9 ± 11.9 years [\pm SD] in NMDAR-E patients (3 M, 21 F), 34.4 ± 13.5 years in their controls (10 M, 23 F), 68.7 ± 13.1 years in LGI1-E patients (8 M, 5 F) and 69.2 ± 10.5 years in their controls (13 M, 5 F). Additional clinical and treatment data are provided in Table 1.

NMDAR-E patients had reduced frequencies of NR1-reactive T cells

All patients and controls had similar frequencies of total CD4⁺ T cells in PBMCs (Fig. 1c, d). As expected, elder cohorts had more memory and less naïve CD4⁺ T cells than younger subjects, equally for patients and healthy controls (Fig. 1e, f).

After incubation of PBMCs with commercially available full-length extracellular NR1 protein in a small pilot cohort, antigen-reactive CD154-expressing CD4⁺ cells were isolated via magnetic cell separation and determined with flow cytometry (Fig. 2a). As a quality control, duplicate measurements of *C. albicans* stimulation from eight patients on the same day showed high correlation of CD154⁺ cell frequencies (Fig. 2b). T cells reactive to fulllength NR1 protein were significantly reduced in patients with NMDAR-E compared to controls (Fig. 2c), suggesting that further experiments including smaller epitopes of NR1 might be informative. The levels of inflammatory cytokines in CD154⁺ (Fig. 2d) and CD4⁺ cells (Fig. 2e) were not significantly different between groups.

NMDAR-E patients had reduced frequencies of CD154⁺ T cells reactive to the extracellular S1S2 domain of the NMDAR

Following the unexpected observation that NR1-reactive CD154-expressing CD4⁺ T cells were reduced in NMDAR-E, we next examined the antigen reactivity to smaller regions of the extracellular NR1 domains (Fig. 1a, b) in a larger cohort of patients. Four patients from the first experiment were available plus nine newly recruited patients with NMDAR-E. We selected the aminoterminal domain (ATD) - the main target epitope of pathogenic autoantibodies in NMDAR-E - and the S1+S2 domains, which are the extracellular parts of the NMDAR NR1 subunit. T cells reactive to the S1S2 domain and to the combination of ATD and S1S2 were significantly reduced in patients with NMDAR-E compared to controls (Fig. 3a). Although not reaching statistical significance, a similar trend was detected after stimulation with ATD alone. In contrast, patients with NMDAR-E and healthy controls showed no difference in T cells responding to the synaptic protein LGI1 or the neoantigen keyhole limpet haemocyanin (KLH) (Fig. 3a). As expected, the absolute frequency of KLH-specific cells was lower compared to NR1-specific cells [1].

Reduced production of inflammatory cytokines in NMDAR-E CD154⁺ T cells

We next determined whether antigen-activated T cells from patients with NMDAR-E differed in the expression levels of inflammatory cytokines. CD4⁺ T cells showed significantly reduced frequencies of TNF α^+ after incubation with ATD, S1S2 proteins and the combination of both stimulations (Fig. 3b). No difference was observed in the TNF α^+ production of CD4⁺ T cells from NMDAR-E patients reactive to KLH and LGI1 (Fig. 3b).

A qualitatively similar picture was seen when comparing the expression of IFN γ^+ CD154⁺ T cells between patients with NMDAR-E and controls. ATD, S1S2 and the combination of both proteins elicited a significantly smaller IFN γ response in patients compared to healthy subjects (Fig. 3c), while the frequencies of IFN γ^+ cells



Fig. 2 Antigen-specific CD154⁺ CD4⁺ T cells in NMDAR-E in a pilot study. Frequencies of antigen-reactive CD154-expressing T cells (exemplary flow cytometry gating after isolation of antigen-reactive CD154-expressing CD4⁺ cells) in **a** were decreased in NMDAR-E patients compared to controls after stimulation with recombinant full-length extracellular NR1 protein (**c**). Percentage of TNF α (**d**) and

after KLH and LGI1 incubation were equal between both groups (Fig. 3c).

No changes of antigen-reactive T cells in LGI1-E patients

To determine whether reduced frequencies of antigen-reactive T cells are a common phenotype across autoimmune encephalitides, we expanded our study to LGI1-E, the second most common form after NMDAR-E. However, patients with LGI1-E did not show an altered frequency of T cells reactive to full-length LGI1 (Fig. 4a), suggesting diseasespecific effects in NMDAR-E patients. Also in contrast to NMDAR-E, TNF α - and IFN γ -positive T cells after stimulation with the disease-defining antigen LGI1 were not altered in LGI1-E patients and controls (Fig. 4b, c).

IFN γ -expressing (e) antigen-specific CD4⁺ T cells was not different between NMDAR-E patients and controls after stimulation with fulllength NR1. As a quality control, biological replicates of *C. albicans* stimulation from PBMCs of the same patient showed robust correlation of CD154⁺ T cell frequencies in separate measurements, indicating low variability in the assay system (**b**)

Diminished antigen-specific CD154⁺ T cell frequencies are not related to immunosuppression

To exclude that the reduction in NR1-activated T cells in NMDAR-E patients is related to previous treatments with immunosuppression, we next determined the T cell activation by the ubiquitously available *Candida albicans* antigen to which typically all people have strong T cell reactivity [1, 12]. No differences were observed in the frequency of *Candida*-specific CD154-expressing T cells of patients with NMDAR-E, LGI1-E and both healthy control groups (Fig. 5a). Similarly, the production of TNF α and IFN γ was not different between all four groups (Fig. 5b) suggesting unimpaired immune function in patients.

Fig. 3 T cell reactivity to fragments of extracellular NR1 and reduced ► inflammatory cytokine production of CD154⁺ CD4⁺ T cells in NMDAR-E patients. Using smaller regions of the extracellular NR1 domain in an expanded cohort of patients with NMDAR-E, frequencies of antigen-reactive CD154-expressing T cells were significantly decreased compared to controls after stimulation with the extracellular proteins S1S2 or the combination of ATD and S1S2, but did not reach statistical significance with ATD alone (a, left). Numbers of antigen-reactive T cells to the neoantigen KLH or the synaptic protein LGI1 were not different in NMDAR-E patients (a, right; logarithmic frequencies within CD4⁺ T cells). Antigen-specific CD154⁺CD4⁺ T cells from NMDAR-E patients showed significantly lower percentages of TNF α -expressing cells after stimulation with ATD, S1S2 or ATD+S1S2 compared to healthy controls, but not after stimulation with KLH or LGI1 control proteins (b). Similarly, antigen-specific T cells from NMDAR-E patients showed significantly lower percentages of IFNy-expressing cells after stimulation with ATD, S1S2 or ATD+S1S2 compared to controls, but not after KLH or LGI1 stimulation (c)

Discussion

The present study is to our knowledge the first direct ex vivo quantitative and qualitative analysis of circulating autoreactive T cells involved in NMDA receptor encephalitis. Our data reveal the unexpected finding that NR1-reactive CD4⁺ T_H cells are not elevated but rather reduced in patients with NMDAR-E and that these cells produce less inflammatory cytokines. No difference was seen in T_H cells reactive to the synaptic target LGI1, ubiquitously available *Candida* antigens or neoantigens when comparing NMDAR-E patients with controls. In contrast, patients with LGI1-E did not have reduced inflammatory cytokines and T_H cell frequencies against their disease-defining antigen LGI1. The data collectively suggest that the reduced T_H cell numbers in NMDAR-E are disease-specific.

Based on our findings, reduced NR1-specific T_H cell numbers are not related to therapeutic immunosuppression. Although most patients with NMDAR-E in this cohort received first- and second-line immunotherapy, the T_H cell immune response against the control antigens was unaltered, including reactivity to *Candida* antigens, the neoantigen KLH and the synaptic protein LGI1. The frequencies of autoantigen-specific T_H cells observed here were in the range of previous studies, i.e., 1 in 10^4 – 10^6 T cells [1].

For the selection and production of highly specific and highly affine antibodies, T_H cells generally mediate the T cell-dependent affinity maturation and enhance antibody responses. Given the strong antibody-mediated etiology in NMDAR-E, we therefore expected rather increased numbers of NR1-specific T_H cells and increased expression of inflammatory cytokines as shown in comparable diseases. For example, in the related antibody-defined CNS disease neuromyelitis optica (NMO), T_H cells against the underlying protein aquaporin-4 (AQP4) were clonally expanded and demonstrated greater proliferation to AQP4 than T cells



from healthy controls [22]. However, these data were generated following long-term in vitro culture which may select individual T cell clones and significantly alter their phenotypic and functional characteristics. Experimental findings involving AQP4 knockout mice rather suggested that the T



Fig.4 Antigen-specific CD154⁺ CD4⁺ T cells in LG11-E. In contrast to NMDAR-E, patients with LG11-E showed similar frequencies of CD154⁺ T cells after stimulation with its disease-specific full-length

antigen LG11 compared to controls (a). LG11-E patients did not show differences in TNF α or IFN γ production after stimulation with LG11 (b, c)



Fig.5 Equal numbers of T cells reactive to *Candida albicans*. All patients and controls showed similar frequencies of antigen-specific CD154⁺ CD4⁺ T cells after stimulation with the ubiquitous *C. albi*-

cans lysate, indicating that observed differences after NMDAR stimulation were not caused by general immunosuppression (**a**). Similarly, TNF α and IFN γ responses were not different between groups (**b**, **c**)

cell response to AQP4 is normally regulated by stringent mechanisms of central and peripheral tolerance, indicating dysfunctional thymic deletion in NMO [19].

However, contrary to our hypothesis, we found a reduction in NR1-reactive T_H cells and markedly decreased inflammatory cytokines in these cells in patients with NMDAR-E. To characterize T_H frequencies and phenotypes, we focused on the two main cytokines TNF α (produced by all activated T_H cells) and IFN γ (produced by memory T cells). Future studies should include further cytokines, although the low cell frequencies will pose a challenge. It seems possible that T_H cells expressing CD154 (the very important B cell helper molecule) might not be required for NR1 antibody generation, thus extrafollicular B cell activation may occur independently of T cell help, e.g., directly in the brain or in some patients in NMDAR-expressing tumor cells in ovarian teratomas, a common association in women with NMDAR-E [8]. In fact, the finding that pathogenic patient-derived NMDAR antibodies had only few or even lacked somatic hypermutations [23] is consistent with a non-germinal center origin, not seen in monoclonal antibodies of patients with LGI1-E [13]. Pathogenic unmutated antibodies are also in striking contrast to NMO, where AQP4 antibodies lost any detectable binding to AQP4 when they were reverted back to their unmutated germline precursors, indicating the need for somatic hypermutations (and thus involvement of T_H cells) to cause disease [5].

A less likely possibility for the reduced NR1-specific T_{H} cell numbers could be the recruitment to germinal centers in the lymphatic organs, to germinal center-like structures in tumors [8] and brain, or to the brain parenchyma, thus not being detectable in the blood. In the murine model of NMDAR-E following active immunization, CD4⁺ T cells were indeed the predominant class of immune cells in the hippocampus at three weeks [11]. The limited availability of biopsy and autopsy samples will make it very difficult to confirm this hypothesis in humans. T cell receptor sequencing to compare clones between CSF and blood or repeated analyses of the T cell frequencies in the same patients during the disease course might partially help as normalization of cell numbers may occur with time. Theoretically, overstimulation/exhaustion of NR1-specific T_H cells or expansion of regulatory T_{H} cells (T_{reg}) might also lead to reduced numbers of NR1-specific T_H cells. It would be difficult to predict, however, in which way T_{reg} were stimulated in NMDAR-E, keeping in mind that it has not been possible yet to isolate and functionally characterize autoantigen-specific T_{reg} in humans.

Our study further suggests that a similar reduction of T_H cell reactivity toward the disease-defining antigen is not a universal finding in the still expanding types of autoimmune encephalitis. Patients with LGI1-E in the present study did not show altered frequencies of LGI1-reactive T_H cells, and it will be interesting to see the T cell phenotype of additional encephalitides in the future, such as GABA_AR, IgLON5, mGluR5 or Caspr2 encephalitis. It is possible that immuno-genetic factors can influence the profiles of immune cell frequencies and distribution. Interestingly, while LGI1-E was strongly linked to the HLA-DR7 haplotype [17, 21], NMDAR-E showed an association with HLA class II allele DRB1*16:02 in one study, which has previously been found in autoimmune diseases predominantly mediated by autoantibodies [20].

Taken together, we unexpectedly observed a reduced number and profound disease-specific functional alterations of NR1-reactive T_H cells in patients with NMDAR-E that were not related to immunotherapies, challenging the idea that increased pro-inflammatory NMDAR-reactive T_H cells contribute to disease pathogenesis. However, the significant modulation of the autoantigen-specific T cell response clearly reveals an autoimmune reaction in these patients. One may hypothesize that, following an initial priming phase, NR1 autoantibody production might not depend on continuous T cell help. Follow-up studies including T cell receptor sequencing as well as generation and functional characterization of T cell lines are needed to further characterize the dysfunctional cytokine response. **Funding** Open Access funding enabled and organized by Projekt DEAL. The work was supported by the German Research Foundation (DFG) (PR 1274/2-1, PR 1274/3-1, PR 1274/5-1) and by the German Federal Ministry of Education and Research (Connect-Generate 01GM1908D) to H.P.

Compliance with ethical standards

Conflicts of interest On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval Written informed consent was received from participants at the Charité Department of Neurology. All human and animal studies have been approved by the appropriate ethics committee (Charité University Hospital Institutional Review Board) and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Bacher P, Scheffold A (2013) Flow-cytometric analysis of rare antigen-specific T cells. Cytometry A 83:692–701
- Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA, Scheffold A (2013) Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol 190:3967–3976
- Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638
- Byun JI, Lee ST, Moon J, Jung KH, Sunwoo JS, Lim JA, Kim TJ, Shin YW, Lee KJ, Jun JS, Lee HS, Lee WJ, Kim YS, Kim S, Jeon D, Park KI, Jung KY, Kim M, Chu K, Lee SK (2016) Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis. J Neuroimmunol 297:141–147
- Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, Ma AK, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O'Connor KC (2019) Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 142:1598–1615
- Dalmau J, Armangue T, Planaguma J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F (2019) An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol
- Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic

anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36

- Day GS, Laiq S, Tang-Wai DF, Munoz DG (2014) Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol 71:717–724
- Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR (2012) Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 32:11082–11094
- Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404
- Jones BE, Tovar KR, Goehring A, Jalali-Yazdi F, Okada NJ, Gouaux E, Westbrook GL (2019) Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors. Sci Transl Med 11
- Koehler FC, Cornely OA, Wisplinghoff H, Schauss AC, Salmanton-Garcia J, Ostermann H, Ziegler M, Bacher P, Scheffold A, Alex R, Richter A, Koehler P (2018) Candida-Reactive T cells for the diagnosis of invasive candida infection-a prospective pilot study. Front Microbiol 9:1381
- Kornau HC, Kreye J, Stumpf A, Fukata Y, Parthier D, Sammons RP, Imbrosci B, Kurpjuweit S, Kowski AB, Fukata M, Prüss H, Schmitz D (2020) Human cerebrospinal fluid monoclonal LGI1 autoantibodies increase neuronal excitability. Ann Neurol 87:405–418
- 14. Kreye J, Wenke NK, Chayka M, Leubner J, Murugan R, Maier N, Jurek B, Ly LT, Brandl D, Rost BR, Stumpf A, Schulz P, Radbruch H, Hauser AE, Pache F, Meisel A, Harms L, Paul F, Dirnagl U, Garner C, Schmitz D, Wardemann H, Prüss H (2016) Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 139:2641–2652
- Liba Z, Kayserova J, Elisak M, Marusic P, Nohejlova H, Hanzalova J, Komarek V, Sediva A (2016) Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J Neuroinflammation 13:55

- Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J (2011) Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77:589–593
- 17. Mueller SH, Farber A, Prüss H, Melzer N, Golombeck KS, Kumpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Suhs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostasy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbaumer G, Wandinger KP, Leypoldt F (2018) Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol 83:863–869
- Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia E, Aguilar E, Titulaer MJ, Petit-Pedrol M, Jain A, Balice-Gordon R, Lakadamyali M, Graus F, Maldonado R, Dalmau J (2015) Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 138:94–109
- Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS (2016) Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci USA 113:14781–14786
- 20. Shu Y, Qiu W, Zheng J, Sun X, Yin J, Yang X, Yue X, Chen C, Deng Z, Li S, Yang Y, Peng F, Lu Z, Hu X, Petersen F, Yu X (2019) HLA class II allele DRB1*16:02 is associated with anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 90:652–658
- van Sonderen A, Roelen DL, Stoop JA, Verdijk RM, Haasnoot GW, Thijs RD, Wirtz PW, Schreurs MW, Claas FH, Sillevis Smitt PA, Titulaer MJ (2017) Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol 81:193–198
- Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53–64
- 23. Wenke NK, Kreye J, Andrzejak E, van Casteren A, Leubner J, Murgueitio MS, Reincke SM, Secker C, Schmidl L, Geis C, Ackermann F, Nikolaus M, Garner CC, Wardemann H, Wolber G, Prüss H (2019) N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol 85:771–776